Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prestige Consumer Healthcare Inc. filings document material events for an operating consumer healthcare company, including 8-K disclosures on quarterly and year-to-date operating results, financial condition and Regulation FD investor presentations. The filings also cover material agreements, capital-structure matters, governance topics and shareholder voting matters tied to the company’s public-company reporting.
These records frame Prestige’s disclosures around its portfolio of over-the-counter healthcare brands, retail distribution markets, and product or regulatory matters when they are material to the business.
Prestige Consumer Healthcare Inc., through its wholly owned subsidiary Prestige Brands, Inc., issued $400.0 million of 6.250% senior unsecured notes due July 15, 2034. Interest is payable semiannually on January 15 and July 15, beginning January 15, 2027. The notes are guaranteed on a senior unsecured basis by the company and certain existing and future domestic restricted subsidiaries.
The notes are redeemable before and after July 15, 2029 on terms set in the indenture, including optional redemptions with a make-whole premium and the ability to redeem up to 40% using proceeds of certain equity offerings. Upon a defined Change of Control, holders must be offered repurchase at 101% of principal plus accrued interest. The indenture includes customary covenants limiting additional indebtedness, restricted payments, liens, asset sales, mergers and affiliate transactions, subject to exceptions.
Prestige Consumer Healthcare Inc. filed an amended Form 8-K/A to update disclosure around its acquisition of the OTC Wellness Business from Foundation Consumer Brands. The amendment primarily removes an inadvertently included auditor review report and keeps prior 8-K and 8-K/A information otherwise unchanged.
Exhibit 99.2 provides unaudited condensed combined financials for the OTC Wellness Business for the three months ended March 31, 2026. Net sales were $51.7 million versus $50.5 million a year earlier, with net income of $12.6 million compared with $14.8 million.
Prestige Consumer Healthcare Inc. ownership update: Ariel Investments, LLC reports beneficial ownership of 4,868,711 shares of Common Stock, representing 10.3% of the class. The filing shows sole voting power for 4,399,246 shares and sole dispositive power for 4,868,711 shares.
The Schedule 13G/A amendment states Ariel acts for adviser clients; no single client holds an economic interest above 5%.
Prestige Consumer Healthcare Inc. completed its acquisition of Australian skincare company LaCorium Health for approximately $150 million in cash on July 1, 2026, funded with cash on hand and existing credit facilities. LaCorium generates about $40 million in annual revenue and is expected to contribute roughly $12 million in EBITDA once fully integrated.
The company amended its Term Loan Credit Agreement and borrowed $95 million of additional term loans to help finance the acquisition. Prestige also priced a private offering of $400 million in 6.25% senior unsecured notes due 2034, with plans to use the proceeds and cash on hand to redeem all $400 million of existing 5.125% Senior Notes due January 2028. Prestige will report first quarter fiscal 2027 results on August 6, 2026.
Prestige Consumer Healthcare filed an amended report to provide full historical and unaudited pro forma financials for its acquisition of the Breathe Right and related OTC Wellness Business from Foundation Consumer Brands. The purchase price was $1,045.0 million in cash, financed with a matching term loan.
The acquired OTC Wellness Business generated net sales of $196.1 million and net income of $58.2 million for the twelve months ended March 31, 2026. Pro forma combined net sales for that period are $1,284.8 million, with pro forma net income of $180.6 million and diluted EPS of $3.71.
Prestige recorded preliminary identifiable intangible assets of $947.7 million and goodwill of $82.6 million, along with a deferred tax liability of $13.2 million. The filing also details the new Term Loan Credit Agreement and related ABL amendment used to fund the transaction.
Prestige Consumer Healthcare Inc. is asking stockholders to vote at its 2026 Annual Meeting on three items: electing six directors, an advisory Say‑on‑Pay vote on executive compensation, and ratifying PricewaterhouseCoopers LLP as auditor for the year ending March 31, 2027. The board recommends voting FOR all proposals.
The proxy highlights a resilient 2026 performance with revenue of $1,088.7 million, adjusted EPS of $4.38, strong free cash flow of $246 million, and year‑end leverage of 2.6x. Management emphasizes a three‑pillar strategy, disciplined capital allocation, and the acquisition of Breathe Right as key drivers of long‑term value.
Governance features include annual director elections, a majority‑vote and conditional resignation policy, a combined Chair/CEO with a Lead Independent Director, and a majority‑independent, skills‑based board. Executive pay is positioned as pay‑for‑performance, with base salary, an annual cash incentive tied to revenue and profitability, and long‑term incentives delivered entirely in equity. Around 97% of shares supported Say‑on‑Pay in 2025, and the company maintains stock ownership guidelines, a clawback policy, and restrictions on hedging and pledging.
Prestige Consumer Healthcare entered a new Term Loan Credit Agreement and completed a major brand acquisition. The company borrowed $1.045 billion in term loans, used to buy the Breathe Right business and certain other brands for a cash purchase price of $1.045 billion. The loan bears interest at Term SOFR plus 2.00% or an alternate base rate and requires quarterly principal payments of 0.25% of outstanding term loans. A second uncommitted term loan draw of up to $95.0 million and an amended ABL Credit Facility with $225 million in aggregate commitments provide additional liquidity, including for the planned LaCorium Health acquisition. Prestige’s press release notes the Breathe Right deal is valued at approximately $900 million net of anticipated tax benefits of $150 million, and that Breathe Right will become its largest brand in a new product category.
Prestige Consumer Healthcare develops, markets and distributes over-the-counter health and personal care brands across North America and select international markets. North American OTC Healthcare generated 83.9% of net revenues in 2026, with International OTC Healthcare contributing 16.1%.
Major brands such as BC and Goody’s, Chloraseptic, Clear Eyes, Compound W, Dramamine, Fleet, Gaviscon, Monistat, Nix and Summer’s Eve give the company leading positions in many niche categories. In 2026, about 63.7% of total revenues came from brands holding a number one market position, and approximately 83.5% of revenues came from major brands.
The company grows through organic innovation and acquisitions, including the 2026 purchase of sterile ophthalmic manufacturer Pillar5 and a signed agreement to acquire OTC brands such as Breathe Right and Dimetapp. Key risks include heavy reliance on third-party manufacturers, concentrated sourcing from one supplier that produced about 21% of gross revenues, inflationary input costs, and customer concentration, with Walmart and Amazon representing roughly 20% and 15% of 2026 gross revenues. Prestige also faces regulatory, supply chain and sustainability-related pressures that could affect margins and product availability.
Prestige Consumer Healthcare Inc. executive Christine Sacco, the company’s CFO and COO, reported a tax-withholding disposition of 1,091 shares of common stock at a price of $55.09 per share. This adjustment reflects a correction to an earlier inadvertent error and leaves her holding 57,374 shares directly.